Updating results

Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]

In development [GID-TA10110] Expected publication date: TBC

Technology appraisal guidance In development

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Technology appraisal guidance Proposed

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

In development [GID-TA10272] Expected publication date: TBC

Technology appraisal guidance In development

Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Technology appraisal guidance In development

Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

In development [GID-TA10046] Expected publication date: 22 November 2017

Technology appraisal guidance In development

Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

In development [GID-TA10065] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Kidney transplantation (rejection) - belatacept [ID87]

In development [GID-TAG239] Expected publication date: TBC

Technology appraisal guidance In development

DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]

In development [GID-TA10143] Expected publication date: TBC

Technology appraisal guidance In development

Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

In development [GID-TA10081] Expected publication date: TBC

Technology appraisal guidance In development

Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

In development [GID-TA10088] Expected publication date: 27 December 2017

Technology appraisal guidance In development

Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Technology appraisal guidance In development

Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

In development [GID-TA10087] Expected publication date: 27 December 2017

Technology appraisal guidance In development

Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

In development [GID-TA10070] Expected publication date: TBC

Technology appraisal guidance In development

Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

In development [GID-TAG526] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]

In development [GID-TA10045] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Technology appraisal guidance In development

KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Diagnostics guidance In development

Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Technology appraisal guidance In development

Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

NICE guideline In development

Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

NICE guideline In development

Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

NICE guideline In development

Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Technology appraisal guidance In development

Osteoporosis (postmenopausal women) - abaloparatide [ID882]

In development [GID-TA10071] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]

In development [GID-TAG479] Expected publication date: TBC

Technology appraisal guidance In development

Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]

In development [GID-TA10171] Expected publication date: TBC

Technology appraisal guidance In development

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Peramivir for treating influenza [ID828]

In development [GID-TA10155] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

In development [GID-TA10177] Expected publication date: TBC

Technology appraisal guidance In development

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

In development [GID-TA10159] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide for untreated follicular lymphoma ID1245

In development [GID-TA10308] Expected publication date: TBC

Technology appraisal guidance In development

Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

In development [GID-TA10353] Expected publication date: TBC

Technology appraisal guidance In development

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Constipation (opioid induced) - methylnaltrexone bromide [ID700]

In development [GID-TA10003] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]

In development [GID-TA10008] Expected publication date: TBC

Technology appraisal guidance In development

Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

NICE guideline In development

Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

In development [GID-TA10236] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Technology appraisal guidance In development

Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

NICE guideline In development